Boehringer Ingelheim Ditches Phase II Alzheimer's Program Post author:Sam Post published:February 8, 2018 Post category:BioPharma Another potential treatment for Alzheimer’s disease has been tossed into the rubbish bin. Source: BioSpace You Might Also Like 6 Biotechs Set Up Shop and Create Jobs in Buffalo, New York February 26, 2017 Belgium Biotech Ablynx Files For $150 Million U.S. IPO Right After Phase III Boost October 2, 2017 NeoTract, Inc.'s Minimally Invasive UroLift System For Enlarged Prostate Now Shown To Be Durable Through Five Years: Results From Pivotal L.I.F.T. Randomized Study Presented March 26, 2017
NeoTract, Inc.'s Minimally Invasive UroLift System For Enlarged Prostate Now Shown To Be Durable Through Five Years: Results From Pivotal L.I.F.T. Randomized Study Presented March 26, 2017